Enteric-coated capsules (≈0.2 ml) before meals.
⏱ 3 min read
Peppermint essential oil (Mentha × piperita) in enteric-coated capsules is one of the few phytotherapeutic preparations with clinical data of sufficient quality to have been formally included in gastroenterology clinical guidelines for the treatment of irritable bowel syndrome; it is a paradigmatic case of how a specific preparation (not bulk oil or leaf infusion) with adequate pharmaceutical technique (enteric coating) can achieve reproducible clinical efficacy and turn the age-old traditional use of mint as a digestive aid into an intervention backed by randomized trials, meta-analyses, and formal guidelines.
The main active principle is menthol, which acts as a calcium channel blocker in intestinal smooth muscle, producing relaxation of the spastic contractions that characterize irritable bowel syndrome and functional abdominal pain; the enteric coating is pharmaceutically critical because it prevents the oil from being released in the stomach (where it would produce reflux, heartburn, and intense minty belching) and allows release in the small intestine and colon, where the antispasmodic effect is exerted at the relevant site.
The indication with the most solid clinical backing (included in guidelines of the American Gastroenterological Association, the British NICE, and others) is the treatment of irritable bowel syndrome: multiple meta-analyses have confirmed significant reductions in abdominal pain, bloating, defecatory urgency, and overall symptoms with doses of 0.2-0.4 milliliters of oil three times a day for 4-12 weeks, with a number needed to treat (NNT) between 2.5 and 3 (that is, for every 2-3 people treated, one experiences a clinically relevant improvement), a notable efficacy for an indication notoriously refractory to available interventions.
A meta-analysis published in the BMJ in 2008 with 9 trials confirmed that enteric-coated peppermint oil was significantly more effective than placebo in IBS; later studies with advanced colon-targeted release formulations (IBgard) have strengthened the evidence with consistent effect sizes.
In functional dyspepsia, especially combined with caraway oil (a well-studied European formulation), enteric-coated peppermint oil has shown efficacy comparable to some pharmacological prokinetics in several European trials; the effects on early satiety, postprandial fullness, and epigastric pain are significant and replicable.
In infantile colic and functional abdominal pain in children and adolescents, several small studies have documented improvements with specific pediatric preparations, an indication with moderate clinical backing but frequent clinical practice in integrative pediatric gastroenterology.
In upper gastrointestinal endoscopy, administering peppermint oil at the time of the procedure reduces gastric and intestinal spasm, improving visualization and technical ease; this specific indication is supported by several studies and is used in some endoscopy centers as an alternative to synthetic antispasmodic drugs.
The dose studied for IBS is 0.2-0.4 milliliters of oil (equivalent to 180-225 mg) three times a day before meals for 4-12 weeks; typical commercial products are enteric-coated capsules of 180-225 mg each (Mintec, Colpermin, IBgard, and others); the enteric coating is absolutely critical for clinical efficacy and for avoiding reflux: non-enteric capsules or bulk oil are significantly less effective and much more poorly tolerated; the effect on symptoms appears progressively and is optimal after 4-12 weeks of continued use.
Generally well tolerated with the appropriate enteric formulation; the most frequent adverse effects are anal burning (if the enteric coating releases late and the menthol reaches the anus unmetabolized), minty belching (if the coating fails and the oil is released prematurely in the stomach), and, occasionally, worsening of gastroesophageal reflux; people with severe hiatal hernia or active gastroesophageal reflux should be cautious because of the risk of worsening; people with gallstones may have worsening of pain because of the choleretic effect; those taking drugs whose absorption may be affected (some antacids, high-dose proton pump inhibitors) should space the doses apart because the rise in gastric pH can prematurely degrade the enteric coating; in children under 8 years, the pure essential oil should not be used because of the risk of laryngeal spasm; in pregnancy and breastfeeding it is generally considered safe at the usual therapeutic doses, although it is advisable to consult; products without enteric coating are not interchangeable and should be avoided for therapeutic use in IBS.
Information, not medical advice. Scientific evidence reflects the quality of the studies.